Oramed Pharmaceuticals Inc.

321 articles about Oramed Pharmaceuticals Inc.

• Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

  11/18/2021

  Oramed today announced the formation of a 50/50 joint venture between Genomma Lab and Oramed's majority-owned subsidiary Oravax Medical Inc.

• Oramed to Present at H.C. Wainwright 7th Annual Israel Conference

  11/11/2021

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present a company overview at the H.C. Wainwright 7th Annual Israel Virtual Conference.

• Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

  11/8/2021

  Oramed Pharmaceuticals Inc. today announced that it has closed its previously announced registered direct offering of 2,000,000 shares of the Company's common stock

• Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial

  10/29/2021

  Oramed Pharmaceuticals Inc. today announced that its majority-owned subsidiary, Oravax Medical Inc. ( www.ora-vax.com ), has received clearance from the South African Health Products Regulatory Authority to commence patient enrollment in a first in human, Phase 1 clinical trial, for its oral COVID-19 vaccine and preparations to begin the trials are now underway.

• Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare Conference

  9/23/2021

  Oramed Pharmaceuticals Inc. announced today that Chief Executive Officer Nadav Kidron will present a company overview at the Cantor Fitzgerald Global Healthcare Conference, held virtually this year from September 27-30, 2021.

• Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment

  9/15/2021

   Oramed Pharmaceuticals Inc. announced today that it has enrolled over 50% of patients planned for its Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis (NASH).

• Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

  9/9/2021

  Oramed Pharmaceuticals Inc. announced today that Chief Executive Officer Nadav Kidron will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference, on September 13, 2021.

• Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

  8/24/2021

  Oramed Pharmaceuticals Inc. announced today that it has enrolled and randomized over 25% of the planned 450 patients for its Phase 3 ORA-D-013-2 trial of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).

• Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

  8/16/2021

  Oramed Pharmaceuticals Inc. today announced that Diabetes, Obesity, and Metabolism, has published an original article titled "Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes mellitus

• MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

  8/10/2021

  MyMD Pharmaceuticals, Inc. reported that its subsidiary Oravax Medical Inc., partially owned with its majority partner Oramed Pharmaceuticals Inc., is preparing to commence clinical trials for its oral COVID-19 vaccine, first in Israel, then in additional clinical sites internationally.

• Oramed to Present at Canaccord Genuity's 41st Annual Growth Conference

  8/9/2021

  Oramed Pharmaceuticals Inc. announced today that Chief Commercial Officer Michael Rabinowitz will present a company overview at Canaccord Genuity's 41st Annual Growth Conference, held virtually this year from August 10-12, 2021.

• Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena International Vaccines Virtual Conference 2021

  8/5/2021

  Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that its majority-owned company Oravax Medical Inc.'s oral COVID-19 vaccine will be featured in the Keynote Talk at the Arena International Vaccines Virtual Conference 2021 on August 5, 2021, at 9:00 a.m. Eastern.

• Oramed Pharmaceuticals Appoints Chief Commercial Officer

  7/29/2021

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Michael Rabinowitz to the newly created position of Chief Commercial Officer effective August 1, 2021.

• 

  COVID-19 Vaccine To Commence Trials in Israel, Oral Version Underway

  7/23/2021

  Oramed Pharmaceuticals said that its majority-owned firm Oravax Medical would be spearheading the project, first in Israel and later in other international clinical locations. 

• Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

  7/21/2021

  Oramed Pharmaceuticals Inc. today announced several updates for its majority-owned company Oravax Medical Inc.

• Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

  6/22/2021

  Oramed Pharmaceuticals Inc. announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index .

• Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

  6/8/2021

  First and Largest of two concurrent Phase 3 trials on track to complete randomization by Q4 2021

• Oramed Issues Letter to Shareholders with Updates on Oral Insulin and COVID-19 Vaccine

  5/25/2021

  - Phase 3 Studies of Oral Insulin Underway and on Schedule - Oral COVID-19 Vaccine Clinical Trials Through Oravax Medical to Begin H2 2021

• Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners' Grand Rounds: A Webinar in Biotech and Specialty Pharma

  4/21/2021

   Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that CEO Nadav Kidron will be featured in a live webinar titled Grand Rounds: a Webinar in Biotech and Specialty Pharma hosted by James Molloy

• Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA's Approved Dual Concurrent Protocol

  3/23/2021

   Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in its ORA-D-013-2 study, the second of two concurrent Phase 3 studies of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).